Patents by Inventor Malcolm Stuart Nobbs

Malcolm Stuart Nobbs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrazine compounds
    Patent number: 6599905
    Abstract: Compounds of formula (I) where R1 is phenyl substituted by one or more halogen atoms, naphthyl and naphthyl substituted by one or more halogen atoms; R2 is —NH2 and —NHC(═O)Ra; R3 is —NRbRc, —NHC(═O)Ra or hydrogen; R4 is hydrogen, —C1-4 alkyl, —CN, —CH2OH, —CH2ORd, —CH2S(O)xRd and —C1-4 alkyl substituted by one or more halogen atoms in which Ra represents C1-4 alkyl or C3-7cycloalkyl, and Rb and Rc, which may be the same or different, are hydrogen or C1-4 alkyl, or together with the nitrogen atom to which they are attached, form a 6-membered nitrogen containing heterocycle, which heterocycle can be further substituted with one or more C1-4 alkyl; Rd is C1-4 alkyl or C1-4 alkyl substituted by one or more halogen atoms; x is an integer zero, one or two; and salts, solvates and prodrugs thereof, provided that R1 does not represent: when R2 is —NH2, and both R3 and R4 are hydrogen.
    Type: Grant
    Filed: May 16, 2001
    Date of Patent: July 29, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Brian Cox, Dean David Edney, Michael Simon Loft, Malcolm Stuart Nobbs, Gita Punjabhai Shah
  • Medical use
    Patent number: 6548507
    Abstract: The present invention relates to the use of sodium channel antagonists in the treatment of diseases mediated by, or exacerbated by, neuronal apoptosis, in particular sensory neuronal apoptosis.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: April 15, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Charanjit Bountra, Malcolm Stuart Nobbs
  • Pyrazine compounds
    Publication number: 20020169172
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: May 16, 2001
    Publication date: November 14, 2002
    Applicant: GLAXO WELLCOME INC.
    Inventors: Brian Cox, Dean David Edney, Michael Simon Loft, Malcolm Stuart Nobbs, Gita Punjabhai Shah
  • Triazine compounds for treatment of CNS disorders
    Patent number: 6465461
    Abstract: A compound of formula (I) and pharmaceutically acceptable prodrugs, salts and solvates thereof.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: October 15, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Brian Cox, Mark Patrick Healy, Malcolm Stuart Nobbs, Gita Punjabhai Shah
  • Triazine compounds for treatment of CNS disorders
    Patent number: 6265405
    Abstract: A compound of formula (I) and pharmaceutically acceptable prodrugs, salts and solvates thereof.
    Type: Grant
    Filed: July 12, 2000
    Date of Patent: July 24, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Brian Cox, Mark Patrick Healy, Malcolm Stuart Nobbs, Gita Punjabhai Shah
  • Pyrazine compounds
    Patent number: 6255307
    Abstract: A compound of formula (I) wherein R1 is selected from the group consisting of phenyl substituted by one or more halogen atoms, naphthyl and naphthyl substituted by one or more halogen atoms; R2 is selected from the group consisting of —NH2 and —NHC(═O)Ra; R3 is selected from the group consisting of —NRbRc, —NHC(═O)Ra and hydrogen, R4 is selected from the group consisting of hydrogen, -C1-4 alkyl, -C1-4 alkyl substituted by one or more halogen atoms, —CN, —CH2OH, —CH2ORd and —CH2S(O)xRd; wherein Ra represents C1-4 alkyl or C3-7cycloalkyl, and Rb and Rc, which may be the same or different, are selected from hydrogen and C1-4 alkyl, or together with the nitrogen atom to which they are attached, form a 6-membered nitrogen containing heterocycle, which heterocycle can be further susbtituted with one or more C1-4 alkyl; Rd is selected from C1-4 alkyl or C1-4 alkyl substituted by one or more halogen atoms; x is an integer zero, one or two; and pharmaceuticall
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: July 3, 2001
    Assignee: Glaxo Wellcome, Inc.
    Inventors: Brian Cox, Dean David Edney, Michael Simon Loft, Malcolm Stuart Nobbs, Gita Punjabhai Shah
  • Optically active phenyl pyrimidine derivatives as analgesic agent
    Patent number: 6124308
    Abstract: A pyrimidine of formula (I) ##STR1## and its pharmaceutically acceptable acid addition salts are useful as analgesics, as anticonvulsants or in the treatment of irritable bowel syndrome or bipolar disorder.
    Type: Grant
    Filed: February 26, 1998
    Date of Patent: September 26, 2000
    Assignee: Glaxo Wellcome Inc.
    Inventors: Malcolm Stuart Nobbs, Sandra Jane Rodgers
  • 2-(n-alkylpiperazino or morpholino)-4-amino-5-aryl-pyrimidines
    Patent number: 5712276
    Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 27, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Alistair Ainslie Miller, Malcolm Stuart Nobbs, Richard Martin Hyde, Michael John Leach
  • Pharmacologically active CNS compounds
    Patent number: 5684005
    Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 4, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Alistair Ainslie Miller, Malcolm Stuart Nobbs, Richard Martin Hyde, Michael John Leach